NZ333357A - Reduction of cardiotoxicity of an antitumor agent using manganese compound - Google Patents
Reduction of cardiotoxicity of an antitumor agent using manganese compoundInfo
- Publication number
- NZ333357A NZ333357A NZ333357A NZ33335797A NZ333357A NZ 333357 A NZ333357 A NZ 333357A NZ 333357 A NZ333357 A NZ 333357A NZ 33335797 A NZ33335797 A NZ 33335797A NZ 333357 A NZ333357 A NZ 333357A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cardiotoxicity
- reduction
- antitumor agent
- manganese compound
- chelate
- Prior art date
Links
- 206010048610 Cardiotoxicity Diseases 0.000 title abstract 2
- 231100000259 cardiotoxicity Toxicity 0.000 title abstract 2
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 150000002697 manganese compounds Chemical class 0.000 title 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 230000000259 anti-tumor effect Effects 0.000 abstract 2
- 239000013522 chelant Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 abstract 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 abstract 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 abstract 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 abstract 1
- 229960004679 doxorubicin Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052748 manganese Inorganic materials 0.000 abstract 1
- 239000011572 manganese Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preventing Corrosion Or Incrustation Of Metals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Manufacture And Refinement Of Metals (AREA)
- Semiconductor Lasers (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9613182.6A GB9613182D0 (en) | 1996-06-24 | 1996-06-24 | Method |
| PCT/GB1997/001721 WO1997049390A1 (en) | 1996-06-24 | 1997-06-24 | Reduction of cardiotoxicity of an antitumor agent using manganese compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ333357A true NZ333357A (en) | 2000-08-25 |
Family
ID=10795775
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ333357A NZ333357A (en) | 1996-06-24 | 1997-06-24 | Reduction of cardiotoxicity of an antitumor agent using manganese compound |
| NZ333315A NZ333315A (en) | 1996-06-24 | 1997-06-24 | Dipyridoxyl chelating agents and their metal chelates for treating free radicals induced conditions |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ333315A NZ333315A (en) | 1996-06-24 | 1997-06-24 | Dipyridoxyl chelating agents and their metal chelates for treating free radicals induced conditions |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US6147094A (enExample) |
| EP (2) | EP0936915B1 (enExample) |
| JP (2) | JP4162263B2 (enExample) |
| CN (2) | CN1228703A (enExample) |
| AT (2) | ATE225178T1 (enExample) |
| AU (2) | AU720621B2 (enExample) |
| BR (1) | BR9709942A (enExample) |
| CA (2) | CA2258299A1 (enExample) |
| DE (2) | DE69717447T2 (enExample) |
| GB (1) | GB9613182D0 (enExample) |
| IL (1) | IL127733A0 (enExample) |
| NO (2) | NO985916L (enExample) |
| NZ (2) | NZ333357A (enExample) |
| WO (2) | WO1997049409A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9727224D0 (en) * | 1997-12-23 | 1998-02-25 | Nycomed Imaging As | Method |
| JP2001527072A (ja) | 1997-12-23 | 2001-12-25 | ニユコメド・イメージング・アクシエセルカペト | 一酸化窒素を放出するキレート化剤およびその治療上の使用 |
| KR20110049875A (ko) | 1999-10-01 | 2011-05-12 | 디엠아이 바이오사이언시스, 인크 | 금속 결합 화합물 및 그의 용도 |
| US7632803B2 (en) | 1999-10-01 | 2009-12-15 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
| US7592304B2 (en) | 1999-10-01 | 2009-09-22 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
| FR2823977B1 (fr) | 2001-04-26 | 2006-12-01 | Univ Rene Descartes | Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif |
| GB0117645D0 (en) | 2001-07-19 | 2001-09-12 | Isis Innovation | Therapeutic stratergies for prevention and treatment of alzheimers disease |
| US20040038904A1 (en) * | 2002-05-21 | 2004-02-26 | Angela Ogden | Method of treating multiple sclerosis |
| FR2863892B1 (fr) * | 2003-12-18 | 2007-05-11 | Univ Paris Descartes | Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux |
| EP1744764B1 (en) | 2004-04-22 | 2012-05-30 | Celator Pharmaceuticals, Inc. | Liposomal formulations of anthracycline agents and cytidine analogs |
| TR200801337T1 (tr) | 2005-08-31 | 2008-07-21 | Abraxis Bioscience, Llc. | Suda zayıf çözülebilen farmasötik ajanlar ve antimikrobiyal ajanlar içeren kompozisyonlar. |
| KR101678866B1 (ko) * | 2007-12-14 | 2016-11-23 | 플레드파르마 에이비 | 암의 치료에 사용하기 위한 화합물들 |
| ES2665305T3 (es) * | 2009-07-06 | 2018-04-25 | Pledpharma Ab | Composiciones farmacéuticas y métodos terapéuticos que emplean una combinación de un compuesto complejo de manganeso y una forma compleja sin manganeso del compuesto |
| WO2012154861A2 (en) | 2011-05-09 | 2012-11-15 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| BR112014016497B1 (pt) | 2012-01-05 | 2021-02-23 | Pledpharma Ab | complexos de metal misturados, composição farmacêutica compreendendo os mesmos, métodos de produção e uso |
| ES2899643T3 (es) | 2012-10-01 | 2022-03-14 | Mayo Found Medical Education & Res | Tratamientos para el cáncer |
| WO2014068514A1 (en) | 2012-11-02 | 2014-05-08 | Pledpharma Ab | Cancer treatment methods |
| JP6695286B2 (ja) | 2014-06-13 | 2020-05-20 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | リンパ腫の処置 |
| WO2015195476A1 (en) | 2014-06-16 | 2015-12-23 | Mayo Foundation For Medical Education And Research | Treating myelomas |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| EP3399861A4 (en) | 2016-01-07 | 2019-08-07 | Mayo Foundation for Medical Education and Research | METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON |
| EP3413874A4 (en) | 2016-02-12 | 2020-01-22 | Mayo Foundation for Medical Education and Research | TREATMENTS FOR BLOOD CANCER |
| AU2017238118A1 (en) | 2016-03-21 | 2018-10-11 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
| EP3432926A4 (en) * | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | METHOD FOR REDUCING THE TOXICITY OF CHEMOTHERAPEUTICS |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| JP2019526579A (ja) | 2016-09-01 | 2019-09-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ | Ｔ細胞癌を標的とする為の方法及び組成物 |
| KR20220151022A (ko) | 2016-09-01 | 2022-11-11 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물 |
| EP3509635A1 (en) | 2016-09-06 | 2019-07-17 | Vavotar Life Sciences LLC | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| RU2756892C2 (ru) | 2016-09-06 | 2021-10-06 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения |
| JP2019526587A (ja) | 2016-09-06 | 2019-09-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ | Ｐｄ−ｌ１を発現する癌を処置する方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES444380A1 (es) * | 1976-01-16 | 1977-06-16 | Gosalvez Mario | Un procedimiento para preparar derivados metalicos antraci- clinicos. |
| US4935518A (en) * | 1987-05-08 | 1990-06-19 | Salutar, Inc. | Manganese(II), chelate contrast agents derived from N,N'-bis-(pyridoxal ethylene diamine-N,N')-diacetic acid and derivatives thereof |
| US5223243A (en) * | 1987-05-08 | 1993-06-29 | Salutar, Inc. | Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents |
| US4842845A (en) * | 1987-05-08 | 1989-06-27 | Salutar, Inc. | Radioactive metal chelates for dipyridoxyl phosphate |
| US6204259B1 (en) * | 1993-01-14 | 2001-03-20 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
-
1996
- 1996-06-24 GB GBGB9613182.6A patent/GB9613182D0/en active Pending
-
1997
- 1997-06-24 AT AT97928369T patent/ATE225178T1/de not_active IP Right Cessation
- 1997-06-24 AU AU32689/97A patent/AU720621B2/en not_active Ceased
- 1997-06-24 IL IL12773397A patent/IL127733A0/xx unknown
- 1997-06-24 WO PCT/GB1997/001722 patent/WO1997049409A1/en not_active Ceased
- 1997-06-24 EP EP97928369A patent/EP0936915B1/en not_active Expired - Lifetime
- 1997-06-24 CA CA002258299A patent/CA2258299A1/en not_active Abandoned
- 1997-06-24 CN CN97197438A patent/CN1228703A/zh active Pending
- 1997-06-24 NZ NZ333357A patent/NZ333357A/xx unknown
- 1997-06-24 CA CA002259150A patent/CA2259150A1/en not_active Abandoned
- 1997-06-24 WO PCT/GB1997/001721 patent/WO1997049390A1/en not_active Ceased
- 1997-06-24 DE DE69717447T patent/DE69717447T2/de not_active Expired - Lifetime
- 1997-06-24 AU AU32688/97A patent/AU720570B2/en not_active Ceased
- 1997-06-24 JP JP50255898A patent/JP4162263B2/ja not_active Expired - Lifetime
- 1997-06-24 AT AT97928368T patent/ATE228361T1/de not_active IP Right Cessation
- 1997-06-24 CN CN97197429A patent/CN1228694A/zh active Pending
- 1997-06-24 NZ NZ333315A patent/NZ333315A/xx unknown
- 1997-06-24 JP JP50255798A patent/JP4359651B2/ja not_active Expired - Lifetime
- 1997-06-24 EP EP97928368A patent/EP0910360B1/en not_active Expired - Lifetime
- 1997-06-24 BR BR9709942A patent/BR9709942A/pt not_active Application Discontinuation
- 1997-06-24 DE DE69716104T patent/DE69716104T2/de not_active Expired - Lifetime
-
1998
- 1998-12-17 US US09/213,246 patent/US6147094A/en not_active Expired - Lifetime
- 1998-12-17 NO NO985916A patent/NO985916L/no not_active Application Discontinuation
- 1998-12-17 US US09/213,290 patent/US6258828B1/en not_active Expired - Lifetime
- 1998-12-17 NO NO985917A patent/NO985917L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO985916L (no) | 1999-01-25 |
| JP2000513351A (ja) | 2000-10-10 |
| ATE228361T1 (de) | 2002-12-15 |
| NO985916D0 (no) | 1998-12-17 |
| JP4162263B2 (ja) | 2008-10-08 |
| CA2259150A1 (en) | 1997-12-31 |
| WO1997049409A1 (en) | 1997-12-31 |
| NO985917D0 (no) | 1998-12-17 |
| US6147094A (en) | 2000-11-14 |
| DE69717447D1 (de) | 2003-01-09 |
| IL127733A0 (en) | 1999-10-28 |
| NZ333315A (en) | 2000-07-28 |
| CN1228694A (zh) | 1999-09-15 |
| NO985917L (no) | 1999-01-25 |
| US6258828B1 (en) | 2001-07-10 |
| EP0910360A1 (en) | 1999-04-28 |
| EP0936915A1 (en) | 1999-08-25 |
| DE69716104D1 (de) | 2002-11-07 |
| DE69716104T2 (de) | 2003-05-28 |
| AU720621B2 (en) | 2000-06-08 |
| EP0936915B1 (en) | 2002-10-02 |
| EP0910360B1 (en) | 2002-11-27 |
| GB9613182D0 (en) | 1996-08-28 |
| JP4359651B2 (ja) | 2009-11-04 |
| JP2000514044A (ja) | 2000-10-24 |
| AU3268897A (en) | 1998-01-14 |
| DE69717447T2 (de) | 2003-09-11 |
| CN1228703A (zh) | 1999-09-15 |
| BR9709942A (pt) | 1999-08-10 |
| ATE225178T1 (de) | 2002-10-15 |
| AU720570B2 (en) | 2000-06-08 |
| AU3268997A (en) | 1998-01-14 |
| CA2258299A1 (en) | 1997-12-31 |
| WO1997049390A1 (en) | 1997-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ333357A (en) | Reduction of cardiotoxicity of an antitumor agent using manganese compound | |
| AU3784193A (en) | Reduction of swelling in hemorrhoidal tissues | |
| CA2234282A1 (en) | Drug-resin complexes stabilized by chelating agents | |
| CA2222676A1 (en) | New pharmaceutical composition with anaesthetic effect | |
| CA2086429A1 (fr) | Composition pharmaceutique ou cosmetique contenant en association un retinoide et un sterol | |
| AU4254696A (en) | Novel substituted dtpa derivatives, their metal complexes, pharmaceutical compositions containing these complexes and their use in diagnosis and therapy | |
| ZA945546B (en) | Antifugal nail solution | |
| AU2223495A (en) | Spiro compound and medicinal composition thereof | |
| CA2001765A1 (en) | Chelants possessing ortho ligating functionality and complexes thereof | |
| AU6959694A (en) | Antineoplastic compositions and methods of use | |
| AU6527594A (en) | Oral glutamine to reduce stomatitis | |
| AU8739791A (en) | Improved anti-plaque compositions comprising a combination of morpholinoamino alcohol and chelating agent | |
| GB2289472B (en) | CRT adhesive composition and CRT obtained by the use thereof | |
| WO1996041627A3 (en) | Iron compounds, compositions, methods of making the same and uses thereof | |
| AU3892593A (en) | Composition for therapeutic or diagnostic use, process for its preparation and its use | |
| CA2116829A1 (en) | Use of a pregnane derivative | |
| AU7997491A (en) | Extended-release plaque preventing and dissolving compositions and their method of use | |
| GR3033999T3 (en) | New compounds with analgesic and local anaesthetic effect | |
| AU2729192A (en) | Carboxyalkyl polysaccharides having improved absorbent properties and process for the preparation thereof | |
| AU2022595A (en) | Anti-sun cosmetic composition based on a synergic mixture ofscreening agents and uses | |
| AU4563093A (en) | Echographic contrast agent composition | |
| IL116733A (en) | Sertraline for use as an anticancer agent compositions containing same preparation and uses thereof | |
| AU1214792A (en) | Chelates, their metal complexes as well as their use in diagnosis and treatment | |
| AU2554595A (en) | Compositions and uses thereof in the diagnosis of psoriasis | |
| AU6777194A (en) | Water soluble derivatives of camptothecin and their use as antitumor agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) |